Histogenics (HSGX) IPO Prices at $11, Below Expected Range

Histogenics Corporation (NASDAQ: HSGX) priced its initial public offering of 5,909,091 shares of its common stock at a price to the public of $11.00 per share, below the expected $13.00-$15.00 range. The offering size was raised from 4,285,714. The shares are expected to begin trading today on the NASDAQ Global Market under the ticker symbol "HSGX". Trading is currently expected at approximately 10:25AM ET.

Cowen and Company, LLC, Needham & Company, LLC and Canaccord Genuity Inc. are acting as the joint book-running managers and BTIG, LLC is acting as co-manager for the offering.

Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace. Histogenics' regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. Histogenics' first investigational product candidate, NeoCart®, leverages its platform to provide an innovative treatment in the orthopedic space, specifically cartilage damage in the knee.

You May Also Be Interested In